Research programme: monoclonal antibody therapeutics - Staurus Pharma

Drug Profile

Research programme: monoclonal antibody therapeutics - Staurus Pharma

Alternative Names: Anti SpA-variant IgG1; Staurus 001

Latest Information Update: 16 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Staurus Pharma
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Staphylococcal infections

Most Recent Events

  • 16 Sep 2016 Research progarmme: monoclonal antibody therapeutics - Staurus Pharma is available for licensing as of 16 Sep 2016. http://www.stauruspharma.com/
  • 30 Aug 2016 Preclinical trials in Staphylococcal infections in USA (unspecified route)
  • 03 Aug 2016 Staurus Pharma has patent protection for Fc variant antibodies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top